Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSEPHONE trial of neoadjuvant carboplatin + paclitaxel + tislelizumab in biomarker-selected resectable oral cavity squamous cell carcinoma
2024-517565-16-00Phase 2Authorised
- Sponsor
- GONO Foundation
- Start
- Jul 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, carboplatin and paclitaxel in Oral Mucosal Carcinoma, sponsored by GONO Foundation. Primary endpoint: Major pathological response rate. Planned start Jul 2026; status: authorised.
02
Drugs
tislelizumabcarboplatinpaclitaxel
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on 2024-517565-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517565-16-00.